Vycor Medical, Inc. VYCO
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 418.30K | 458.50K | 416.90K | 513.80K | 496.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 418.30K | 458.50K | 416.90K | 513.80K | 496.40K |
| Cost of Revenue | 73.80K | 83.40K | 81.50K | 61.90K | 81.10K |
| Gross Profit | 344.40K | 375.20K | 335.40K | 451.90K | 415.30K |
| SG&A Expenses | 322.70K | 315.40K | 357.00K | 405.00K | 345.00K |
| Depreciation & Amortization | 14.90K | 14.00K | 14.90K | 14.90K | 14.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 411.40K | 412.70K | 453.40K | 481.70K | 445.20K |
| Operating Income | 6.90K | 45.80K | -36.50K | 32.10K | 51.10K |
| Income Before Tax | -19.10K | 20.10K | -62.40K | 5.00K | 25.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.10K | 20.10K | -62.40K | 5.00K | 25.70K |
| Earnings from Discontinued Operations | -3.20K | 0.00 | -300.00 | -100.00 | -1.80K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.30K | 20.10K | -62.70K | 4.90K | 23.90K |
| EBIT | 6.90K | 45.80K | -36.50K | 32.10K | 51.10K |
| EBITDA | 21.30K | 61.50K | -20.40K | 48.00K | 66.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 33.37M | 33.37M | 33.37M | 33.37M | 33.37M |
| Average Diluted Shares Outstanding | 33.37M | 33.37M | 33.37M | 33.37M | 38.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |